Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company's lead drug candidate, Lucid-MS, and its commercial alcohol metabolism product, unbuzzd™. Durkacz emphasized that Lucid-MS is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage, an area he believes remains unmet by currently available treatments.
According to the press release, Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models—the underlying mechanism of multiple sclerosis. The company is preparing for its upcoming Phase 2 clinical trial, which will be the first study to evaluate the drug candidate in multiple sclerosis patients, following Phase 1 testing in healthy volunteers. This trial represents a critical milestone for Quantum BioPharma as it advances toward potential regulatory approval.
On the commercial front, Durkacz highlighted unbuzzd™, a product designed to accelerate blood alcohol metabolism, which is currently available in the U.S. market. Quantum BioPharma invented unbuzzd™ and spun out its over-the-counter version to Unbuzzd Wellness Inc., led by industry veterans. As of March 31, 2026, Quantum retains a 19.84% ownership stake in Unbuzzd, as noted on the company's website at www.unbuzzd.com. The agreement also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The company's focus on both neurodegenerative and metabolic disorders, as well as alcohol misuse, positions it in multiple high-need therapeutic areas. The potential impact of Lucid-MS is significant given the unmet need in multiple sclerosis treatment, where current therapies primarily address inflammation rather than nerve damage and repair. If successful, Lucid-MS could offer a novel approach to restoring mobility and improving quality of life for MS patients.
For the industry, Quantum BioPharma's dual strategy of advancing a clinical-stage drug candidate while generating revenue from a commercial product provides a balanced risk profile. The unbuzzd™ royalty stream could fund further development of Lucid-MS and other pipeline assets. Investors and stakeholders can find the latest news and updates relating to QNTM in the company's newsroom at https://ibn.fm/QNTM.
The upcoming Phase 2 trial will be closely watched by the medical and investment communities as it provides the first efficacy data in MS patients. Quantum BioPharma's commitment to addressing challenging neurodegenerative disorders underscores its potential to make a meaningful difference in patients' lives while creating value for shareholders.
